K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · MCK
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) | $860K | H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors);S. 3822, Break Up Big Medicine Act; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex |
| 2026-04-20 | MCK | MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) | STANTON PARK GROUP | $60K | Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain; HR4299, Protecting Patient Access to Cancer and Complex Therapies Act. H.R.2484, Seniors Access to Critical Medications Act of 2025 |
| 2026-04-20 | MCK | MCKESSON CORPORATION | TODD STRATEGY GROUP | $50K | General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness. |
| 2026-04-20 | MCK | MCKESSON CORPORATION | MONUMENT ADVOCACY | $50K | Issues around interoperability, data privacy and sharing in healthcare, drug shortages and healthcare transparency, 2026 rule and drug reimbursement changes. |
| 2026-04-20 | MCK | MCKESSON SPECIALTY HEALTH | HOOPER, LUNDY & BOOKMAN, P.C. | $40K | Radiation Oncology payment proposals in the CY 2026 Physician Fee Schedule proposed rule. |
| 2026-04-20 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER | NORTH SOUTH GOVERNMENT STRATEGIES F/K/A JDM PUBLIC STRATEGIES, LLC | $30K | H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Pr |
| 2026-04-15 | MCK | MCKESSON CORPORATION | KOUNTOUPES DENHAM CARR & REID, LLC | $60K | Issues related to the pharmaceutical supply chain and drug shortages. Issues related to H.R. 3164, Ensuring Community Access to Pharmacist Services Act. and S.2426, Equitable Community Access to Pharmacist Services Act. Issues related to pharmacies and patient access. |
| 2026-02-13 | MCK | MCKESSON CORPORATION | MONUMENT ADVOCACY | $0 | Issues around interoperability, data privacy and sharing in healthcare, drug shortages and healthcare transparency, 2026 rule and drug reimbursement changes. |
| 2026-01-20 | MCK | MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) | STANTON PARK GROUP | $60K | Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain. H.R.2484, Seniors Access to Critical Medications Act of 2025 |
| 2026-01-20 | MCK | MCKESSON CORPORATION | TODD STRATEGY GROUP | $50K | General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness. |
| 2026-01-19 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) | $1.2M | H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Pr |
| 2026-01-19 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER | NORTH SOUTH GOVERNMENT STRATEGIES F/K/A JDM PUBLIC STRATEGIES, LLC | $30K | H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Pr |
| 2026-01-16 | MCK | MCKESSON CORPORATION | KOUNTOUPES DENHAM CARR & REID, LLC | $60K | Issues related to the pharmaceutical supply chain and drug shortages. Issues related to H.R. 3164, ensuring Community Access to Pharmacist Services Act. and S.2426, Equitable Community Access to Pharmacist Services Act. |
| 2026-01-16 | MCK | MCKESSON CORPORATION | HORIZON GOVERNMENT AFFAIRS | $50K | Issues around interoperability, data privacy and sharing in healthcare, drug shortages and healthcare transparency, 2026 rule and drug reimbursement changes |
| 2026-01-16 | MCK | MCKESSON SPECIALTY HEALTH | HOOPER, LUNDY & BOOKMAN, P.C. | $40K | Radiation Oncology payment proposals in the CY 2026 Physician Fee Schedule proposed rule. |
| 2025-10-20 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) | $530K | H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Pr |
| 2025-10-20 | MCK | MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) | STANTON PARK GROUP | $60K | Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain. H.R.2484, Seniors Access to Critical Medications Act of 2025 |
| 2025-10-20 | MCK | MCKESSON CORPORATION | TODD STRATEGY GROUP | $50K | General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness. |
| 2025-10-20 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER | NORTH SOUTH GOVERNMENT STRATEGIES F/K/A JDM PUBLIC STRATEGIES, LLC | $30K | H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Pr |
| 2025-10-19 | MCK | MCKESSON SPECIALTY HEALTH | HOOPER, LUNDY & BOOKMAN, P.C. | $40K | Radiation Oncology payment proposals in the CY 2026 Physician Fee Schedule proposed rule. |
| 2025-10-14 | MCK | MCKESSON CORPORATION | KOUNTOUPES DENHAM CARR & REID, LLC | $60K | Issues related to the pharmaceutical supply chain and drug shortages. Issues related to H.R. 3164, ensuring Community Access to Pharmacist Services Act. and S.2426, Equitable Community Access to Pharmacist Services Act. |
| 2025-10-14 | MCK | MCKESSON CORPORATION | HORIZON GOVERNMENT AFFAIRS | $50K | Issues around interoperability, data privacy and sharing in healthcare, drug shortages and healthcare transparency. |
| 2025-07-21 | MCK | MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) | STANTON PARK GROUP | $60K | H.R.2484, Seniors Access to Critical Medications Act of 2025 Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain. |
| 2025-07-21 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER | NORTH SOUTH GOVERNMENT STRATEGIES F/K/A JDM PUBLIC STRATEGIES, LLC | $30K | H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; Inflation Reduction Act (IRA) reform on drug pricing and add on fee (Protecting Patient Access to Cancer and Complex Therapies Act (not reintroduce |
| 2025-07-19 | MCK | MCKESSON CORPORATION | TODD STRATEGY GROUP | $50K | General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness. |
| 2025-07-18 | MCK | MCKESSON SPECIALTY HEALTH | HOOPER, LUNDY & BOOKMAN, P.C. | $40K | |
| 2025-07-17 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) | $460K | H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; Inflation Reduction Act (IRA) reform on drug pricing and add on fee (Protecting Patient Access to Cancer and Complex Therapies Act (not reintroduce |
| 2025-07-17 | MCK | MCKESSON CORPORATION | KOUNTOUPES DENHAM CARR & REID, LLC | $60K | Issues related to the pharmaceutical supply chain and drug shortages. |
| 2025-07-11 | MCK | MCKESSON CORPORATION | HORIZON GOVERNMENT AFFAIRS | $50K | Issues around interoperability, data privacy and sharing in healthcare, drug shortages and healthcare transparency and PBM reform legislation. |
| 2025-04-24 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) | $1.2M | Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities. Last-in, first-out (LIFO) Inventory Accounting Method; H.R.5376 The Inflation Reduction Act Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 44 |
| 2025-04-22 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER | NORTH SOUTH GOVERNMENT STRATEGIES F/K/AJDM PUBLIC STRATEGIES, LLC | $0 | Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparen |
| 2025-04-21 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) | $1.2M | Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act. Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 |
| 2025-04-21 | MCK | MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) | STANTON PARK GROUP | $60K | Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain. H.R.2484, Seniors Access to Critical Medications Act of 2025 |
| 2025-04-21 | MCK | MCKESSON CORPORATION | TODD STRATEGY GROUP | $50K | General Medicare/Medicaid Issues. Prescription Drug Price Reform. Transparency Requirements. Emergency Preparedness. |
| 2025-04-18 | MCK | MCKESSON SPECIALTY HEALTH | HOOPER, LUNDY & BOOKMAN, P.C. | $40K | |
| 2025-04-18 | MCK | MCKESSON CORPORATION | W STRATEGIES, LLC | $10K | Issues related to the drug supply chain, transparency and patient access to medicines. |
| 2025-04-16 | MCK | MCKESSON CORPORATION | HORIZON GOVERNMENT AFFAIRS | $50K | Issues around interoperability, data privacy and sharing in healthcare, drug shortages and healthcare transparency and PBM reform legislation. |
| 2025-04-15 | MCK | MCKESSON CORPORATION | KOUNTOUPES DENHAM CARR & REID, LLC | $40K | Issues related to the pharmaceutical supply chain and drug shortages. |
| 2025-03-27 | MCK | MCKESSON CORPORATION | KOUNTOUPES DENHAM CARR & REID, LLC | $0 | Issues related to health care distribution services |
| 2025-01-21 | MCK | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS | MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) | $560K | H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities. H.R.5376 The Inflation Reduction Act. H.R.5376 The Inflation Reduction Act. H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R. 7623: Telehealth Modernization Ac |
| 2025-01-21 | MCK | MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY) | STANTON PARK GROUP | $60K | Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain. |
| 2025-01-21 | MCK | MCKESSON CORPORATION | W STRATEGIES, LLC | $30K | Issues related to the drug supply chain, transparency and patient access to medicines. H.R.1770 - Equitable Community Access to Pharmacist Services Act. |